Insider trades

Stock that executives, directors and 10% owners bought and sold on the open market, from the Form 4s they file with the SEC within two business days. Grants, option exercises and shares sold to cover taxes are left out.

4,839 companies covered, latest filing Oct 23.

$1.5B bought by 353 insiders at 214 companies
$3.3B sold by 278 insiders outside a trading plan
$7.9B sold by 834 insiders under 10b5-1 plans
10 companies where two or more insiders bought (30 days)

Biggest buys

Past month, each insider's filings added up.

LENLennar

Berkshire Hathaway Inc.10% owner, +1 joint filer

4,758,747 shares at $80.46 Sep 23–Oct 2, 3 filings 3 superinvestors bought in Q2

$383M
CRBGCorebridge Financial

Life Insurance Co Nippon10% owner

6,813,481 shares at $34.22 Sep 21–Oct 21, 22 filings +5.5% to stake 2 superinvestors bought in Q2

$233M
KODKodiak Sciences

Baker Bros. Advisors LPDirector, +5 joint filers

1,941,755 shares at $80.85 Sep 28–29, 3 filings +11% to stake 1 superinvestor sold in Q2

$157M
SAFXXCF Global

EEME Energy SPV I, LLC10% owner

119M shares at $1.19 Oct 16 +109% to stake

$142M
GPIGroup 1 Automotive

Conifer Management, L.L.C.10% owner

400,000 shares at $244.51 Sep 24–30, 2 filings +26% to stake 2 superinvestors bought in Q2

$97.8M
UUUUniversal Safety Products

Milton C Ault IIIDirector

33,434 shares at $2,766.36 Sep 21–30, 2 filings

$92.5M
GMEGameStop

Ryan CohenCEO

1,994,130 shares at $25.29 Sep 29–Oct 13, 3 filings +4.9% to stake

$50.4M
BORRBorr Drilling

Tor Olav TroimDirector

9,500,000 shares at $4.53 Oct 5–15, 7 filings +31% to stake

$43M
PAMPampa Energia

Marcos Marcelo MindlinDirector

435,000 shares at $80.78 Oct 15 +6.4% to stake

$35.1M
GGRGogoro

Chung-Yao YinDirector

14.2M shares at $2.48 Oct 7 New stake

$35.1M

Biggest sales

Past month, each insider's filings added up. Planned sales are marked.

IHTInnSuites Hospitality Trust

James F WirthCEO

86,222 shares at $48,532.59 Oct 7–20, 2 filings 1.1% of stake Planned sale (10b5-1)

$4.2B
MDLNMedline

GIC Private Ltd10% owner, +2 joint filers

28.5M shares at $34.97 Oct 2–8, 2 filings

$996M
ESTCElastic

Steven SchuurmanDirector

3,500,000 shares at $92.43 Oct 5–12, 2 filings 58% of stake

$323M
TALOTalos Energy

Empresarial De Capitales S.a. De C.v. Control10% owner

14.6M shares at $17.33 Oct 6–19, 5 filings 37% of stake

$253M
AVGOBroadcom

Henry SamueliDirector

702,190 shares at $356.04 Sep 23 1.9% of stake Planned sale (10b5-1)

$250M
THTarget Hospitality

TDR Capital II Investments LP10% owner, +9 joint filers

11M shares at $18.40 Oct 1 40% of stake

$202M
ANETArista Networks

Jayshree UllalCEO

778,531 shares at $213.68 Sep 25–Oct 9, 4 filings 4.8% of stake Planned sale (10b5-1)

$166M
KNTKKinetik

ISQ Global Fund II GP LLC10% owner, +4 joint filers

2,448,272 shares at $54.63 Sep 22–Oct 13, 4 filings 100% of stake

$134M
CRWDCrowdStrike

Burt W. PodbereCFO

480,000 shares at $261.44 Sep 24 Planned sale (10b5-1)

$125M
NBISNebius Group

Ophir NaveCOO

500,000 shares at $235.53 Oct 5 52% of stake Planned sale (10b5-1)

$118M

Cluster buying

Companies where two or more insiders bought on the open market in the last 30 days, most buyers first

TSMTaiwan Semiconductor 19 insiders, $80K

Che-Chia Wei CEO, Yuh-Jier Mii COO, Yung-Pei Chin COO, Yung-Chin Hou COO, +15 more

Latest buy Oct 7 19 executives 20 superinvestors sold in Q2
SPGSimon Property Group 11 insiders, $461K

Reuben S Leibowitz Director, Larry C Glasscock Director, Daniel C. Smith Director, Gary M Rodkin Director, +7 more

Latest buy Sep 30
FULH. B. Fuller 9 insiders, $1.1M

R Jeffrey Bailly Director, Daniel L Florness Director, Srilata Zaheer Director, Charles T Lauber Director, +5 more

Latest buy Oct 16 1 executive 1 superinvestor bought in Q2
RAPPRapport Therapeutics 6 insiders, $1.7M

Steven M Paul Director, John Maraganore Director, Troy A. Ignelzi CFO, Wendy B. Young Director, +2 more

Latest buy Oct 23 1 executive
ATCHAtlasClear 5 insiders, $163K

Thomas Jon Hammond Director, Sandip I Patel CFO, John Martin Schaible Chair, David Craig Ridenhour President, +1 more

Latest buy Sep 25 3 executives
RGCORGC Resources 5 insiders, $85K

John B Williamson III Director, Robert B Johnston Director, Paul W Nester CEO, Lawrence T. Oliver Senior VP and Secretary, +1 more

Latest buy Oct 1 3 executives
WVVIWillamette Valley Vineyards 5 insiders, $75K

Michael Jordan Osborn CEO, John Walter Hazlett CFO, Gregory William Voorhies Director, James W Bernau President, +1 more

Latest buy Oct 12 3 executives
MPBMid Penn Bancorp 5 insiders, $25K

Matthew G De Soto Director, Albert J. Evans Director, Kimberly J Brumbaugh Director, Theodore W Mowery Director, +1 more

Latest buy Sep 30
DXDynex Capital 4 insiders, $245K

Smriti Laxman Popenoe CEO, Byron L Boston CEO, Terrence John Connelly Jr. Chief Investment Officer, Michael Andrew Sartori CFO

Latest buy Oct 20 4 executives
ANIXAnixa Biosciences 4 insiders, $203K

Lewis H Titterton Jr. Director, Amit Kumar CEO, Michael Catelani CFO, Arnold M Baskies Director

Latest buy Oct 22 2 executives

CTNM insider trades

Every open-market buy and sale in CTNM, one row per filing, newest first

CTNM page

All Buys Sales

Everyone CEOs CFOs Executives Directors 10% owners

Any size $100K+ $1M+ $10M+

Hide planned sales

Insider

Stock

Trade

Value

Traded, filed
Carmine N. Stengone CEO

CTNMContineum Therapeutics

Planned sale

$41K 2,500 shares at $16.46 13% of stake

Traded Sep 8 Filed Sep 8

↗
Carmine N. Stengone CEO

CTNMContineum Therapeutics

Planned sale

$40K 2,500 shares at $16.01 13% of stake

Traded Aug 3 Filed Aug 3

↗
Daniel S. Lorrain Chief Scientific Officer

CTNMContineum Therapeutics

Planned sale

$17K 1,040 shares at $16.00 0.8% of stake

Traded Jul 8–9 Filed Jul 10

↗
Carmine N. Stengone CEO

CTNMContineum Therapeutics

Planned sale

$40K 2,500 shares at $16.00 13% of stake

Traded Jul 8 Filed Jul 8

↗
Daniel S. Lorrain Chief Scientific Officer

CTNMContineum Therapeutics

Planned sale

$595K 37,179 shares at $15.99 22% of stake

Traded Jun 30–Jul 1 Filed Jul 2

↗
Tim Watkins CMO & Head of Development

CTNMContineum Therapeutics

Planned sale

$174K 10,833 shares at $16.02 55% of stake

Traded Jun 30 Filed Jul 1

↗
Carmine N. Stengone CEO

CTNMContineum Therapeutics

Planned sale

$160K 10,000 shares at $16.01 37% of stake

Traded Jun 30 Filed Jul 1

↗
Daniel S. Lorrain Chief Scientific Officer

CTNMContineum Therapeutics

Planned sale

$55K 4,170 shares at $13.16 2.9% of stake

Traded Jun 1 Filed Jun 1

↗
Daniel S. Lorrain Chief Scientific Officer

CTNMContineum Therapeutics

Planned sale

$55K 4,170 shares at $13.12 2.8% of stake

Traded May 1 Filed May 1

↗
Daniel S. Lorrain Chief Scientific Officer

CTNMContineum Therapeutics

Planned sale

$56K 4,170 shares at $13.43 2.7% of stake

Traded Apr 6 Filed Apr 6

↗
Daniel S. Lorrain Chief Scientific Officer

CTNMContineum Therapeutics

Planned sale

$63K 4,170 shares at $15.01 2.7% of stake

Traded Mar 2 Filed Mar 2

↗
Tim Watkins CMO & Head of Development

CTNMContineum Therapeutics

Planned sale

$54K 3,611 shares at $15.02 100% of stake

Traded Mar 2 Filed Mar 2

↗
Carmine N. Stengone CEO

CTNMContineum Therapeutics

Planned sale

$114K 7,100 shares at $16.02 32% of stake

Traded Feb 24–25 Filed Feb 26

↗
Daniel S. Lorrain Chief Scientific Officer

CTNMContineum Therapeutics

Planned sale

$130K 8,124 shares at $16.02 4.9% of stake

Traded Feb 24–25 Filed Feb 26

↗
Daniel S. Lorrain Chief Scientific Officer

CTNMContineum Therapeutics

Planned sale

$1,600 100 shares at $16.00 0.1% of stake

Traded Feb 19 Filed Feb 20

↗
Carmine N. Stengone CEO

CTNMContineum Therapeutics

Planned sale

$6,400 400 shares at $16.00 2.6% of stake

Traded Feb 11 Filed Feb 13

↗
Daniel S. Lorrain Chief Scientific Officer

CTNMContineum Therapeutics

Planned sale

$62K 4,170 shares at $14.94 2.6% of stake

Traded Feb 3 Filed Feb 5

↗
Tim Watkins CMO & Head of Development

CTNMContineum Therapeutics

Planned sale

$51K 3,611 shares at $14.18 100% of stake

Traded Jan 28 Filed Jan 30

↗
Daniel S. Lorrain Chief Scientific Officer

CTNMContineum Therapeutics

Planned sale

$44K 4,170 shares at $10.44 2.5% of stake

Traded Jan 5 Filed Jan 6

↗
Tim Watkins CMO & Head of Development

CTNMContineum Therapeutics

Planned sale

$44K 3,611 shares at $12.06 100% of stake

Traded Dec 29, 2025 Filed Dec 30, 2025

↗
Daniel S. Lorrain Chief Scientific Officer

CTNMContineum Therapeutics

Planned sale

$51K 4,170 shares at $12.23 2.5% of stake

Traded Dec 23, 2025 Filed Dec 30, 2025

↗

About this data

Officers, directors and anyone owning more than 10% of a company must report a trade in its stock on a Form 4 within two business days. We read each filing from SEC EDGAR and link to it on every row.
Only open-market purchases and sales of common stock count here. Stock grants, option exercises, gifts and shares withheld or sold to pay taxes on vesting awards are not decisions to buy or sell, so they are left out.
A planned sale was made under a Rule 10b5-1 trading plan, which the insider set up months in advance. Many executives sell this way on a schedule, so a planned sale says less than one made on the day.
Values are shares times the price reported. When a filing amends an earlier one, the amended trades replace the originals. Related owners (a fund and its manager) who report the same trade separately are shown once.
We cover the 4,839 US companies on our earnings calendar, with a year of history. The superinvestor notes count the featured 13F managers who added or cut the stock in their latest quarter.